On June 2, 2021 Aptamer Science reported the company signed a joint research agreement with bio venture company PINOTBIO to develop anticancer drugs based on Aptamer Drug Conjugate (ApDC) (Press release, Aptamer Sciences, JUN 2, 2021, View Source;idx=127 [SID1234644070]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Both companies plan to accelerate the development of innovative targeted anti-cancer drugs that go beyond the limitations of existing ‘antibody-drug conjugate (ADC)’ technology by linking their respective core technologies, aptamer discovery technology and linker-drug conjugation technology. am.
The ‘Antibody-Drug Conjugate (ADC)’ technology, which has recently been in the spotlight, has difficulty controlling the conjugation of antibodies and drugs, and has limitations in penetrating cancer tissue due to its molecular size, so there is a steady demand for the development of technology to complement this. The situation continues.
Aptamers, a nucleic acid-based material that is attracting attention as a next-generation drug material, show high selectivity and binding ability to targets and have a molecular size that facilitates tissue penetration. In addition, the ability to design chemical reactions that can control the number and location of drug conjugates is considered an advantage of ApDC technology.
Under this agreement, the two companies plan to conduct joint research aimed at developing targeted anticancer drugs for glioblastoma and pancreatic cancer, which have high unmet medical needs. To this end, Aptamer Science will provide optimized cancer cell-targeting aptamers, and Pinobio will provide He will be responsible for conjugation and efficacy evaluation of tamers and drugs.
Dong-il Han, CEO of Aptamer Science, said, "Through joint research with Pinobio, which has its own linker-drug technology, we want to develop a new type of targeted anti-cancer drug that overcomes the limitations of existing ADC technology." He added, "The collaboration between the two companies is a meaningful clinical trial." "We will do our best to ensure that the outcome is favorable," he said.
Doo-young Jeong, CEO of Pinobio, said, "Through joint research with Aptamer Science, we are able to develop ApDC technology using aptamers, which have characteristics differentiated from antibodies, which are existing drug carriers, so we expect to quickly derive innovative candidates and ADC drug technology. "We expect to be able to present a new paradigm," he said.